AR-14034 not checked

Alcon Research

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Neovascular Age-related Macular Degeneration (nAMD)
Main trialPhase 1/2
“The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).”In the company’s words, NCT05769153 on ClinicalTrials.gov

Other drugs for Neovascular Age-related Macular Degeneration (nAMD)

All 56 drugs for Neovascular Age-related Macular Degeneration (nAMD)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Apr 2027 Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AR-14034

Following is part of Solo: you see every change to AR-14034 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in